RA
IDXG

Royce & Associates’s Interpace Biosciences, Inc. Common Stock IDXG Stock Holding History

Royce & Associates’s Portfolio IDXG Stock Details IDXG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-654
Closed -$117K – 1318
2014
Q4 		$117K Sell
654
-5,654
-90% -$1.01M ﹤0.01% 1214
2014
Q3 		$1.51M Sell
6,308
-1,798
-22% -$601K 0.01% 1056
2014
Q2 		$3.55M Sell
8,106
-745
-8% -$344K 0.01% 935
2014
Q1 		$4.05M Hold
8,851
– – 0.01% 929
2013
Q4 		$4.26M Hold
8,851
– – 0.01% 906
2013
Q3 		$4.27M Sell
8,851
-2,256
-20% -$1.08M 0.01% 889
2013
Q2 		$5.22M Buy
+11,107
New +$5.04M 0.02% 834

Other funds holding IDXG

HA
Heartland Advisors Milwaukee, Wisconsin $2.25B AUM 44.61% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PHS
Pekin Hardy Strauss Chicago, Illinois $1.14B AUM 37.36% 1-Year Est. Return
AA
Ancora Advisors Cleveland, Ohio $5.19B AUM 23.19% 1-Year Est. Return
LCM
Leonard Capital Management Vero Beach, Florida $5.25M AUM
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
GT
Glenmede Trust Philadelphia, Pennsylvania $22.7B AUM
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $177B AUM 39.86% 1-Year Est. Return

Royce & Associates's IDXG Position: Q1 2015 in Review

Royce & Associates sold out of Interpace Biosciences, Inc. Common Stock (IDXG) in Q1 2015, closing a stake of 654 shares — an estimated $117K sold.

Royce & Associates first reported a position in IDXG in Q2 2013 and held it in 7 quarters. The position peaked at $5.22M in Q2 2013. 24 funds tracked by Wall St. Rank hold IDXG as of Q1 2015.

  • Royce & Associates reported no remaining Interpace Biosciences, Inc. Common Stock position as of Q1 2015 after selling out during the quarter.
  • Royce & Associates sold 654 Interpace Biosciences, Inc. Common Stock shares in Q1 2015, an estimated $117K.
  • Royce & Associates first reported a position in Interpace Biosciences, Inc. Common Stock in Q2 2013 and held it in 7 quarters.
  • Royce & Associates's Interpace Biosciences, Inc. Common Stock position peaked at $5.22M in Q2 2013.
  • 24 funds tracked by Wall St. Rank held Interpace Biosciences, Inc. Common Stock as of Q1 2015.

Based on Royce & Associates's 13F filing for Q1 2015, filed 13 May 2015.